Status:
NOT_YET_RECRUITING
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
Lead Sponsor:
University Hospital, Rouen
Conditions:
Monoclonal Gammopathy of Undetermined Significance
Myeloma Multiple
Eligibility:
All Genders
18+ years
Brief Summary
No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophy...
Detailed Description
This study will characterise the links between rare diseases and complex, chronic diseases. Metabolism can be visualised as a complex network in which the various biomolecules represent metabolic node...
Eligibility Criteria
Inclusion
- Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (\>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement).
- Membership of a social security scheme
- Adult having read and understood the information letter and signed the consent form
Exclusion
- Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship
Key Trial Info
Start Date :
June 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06559033
Start Date
June 1 2025
End Date
April 1 2027
Last Update
June 3 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.